Office Action 1: Notice of Allowance (2025-01-27)

CLAIMS:
AMENDMENT TO THE CLAIMS Please enter the amendments to the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

1-124. (Canceled)2123

125\. (New) An expression vector that encodes and stably expresses in vivo an antibody comprising (a) a light chain variable region comprising complementarity determining regions (CDRs) having the amino acid sequences of SEQ ID NOS: 120, 121, and 44, and (b) a heavy chain variable region comprising CDRs having the amino acid sequences of SEQ ID NOS: 116, 117, and 118.

126\. (New) An expression vector that encodes and stably expresses in vivo an antibody comprising each of a light chain variable sequence of SEQ ID NO: 38 and a heavy chain variable sequence of SEQ ID NO: 37.

127\. (New) An expression vector that encodes and stably expresses in vivo an antibody comprising each of a light chain sequence of SEQ ID NO: 26 and a heavy chain sequence of SEQ ID NO: 24.

128\. (New) The expression vector of any one of claim 125-127, wherein the expression vector comprises a viral based vector.

129\. (New) A method of producing an antibody comprising expressing the expression vector of any one of claims 125-127 in a cell.

130\. (New) The method of claim 129, wherein the cell is a prokaryotic host cell or a eukaryotic host cell.

131\. (New) The method of claim 130, wherein the prokaryotic host cell is Escherichia coli, the eukaryotic host cell is a yeast cell, an animal cell or a plant cell.

132\. (New) The method of claim 131, wherein the yeast cell is Saccharomyces cerevisiae, Schizosaccharomyces pombe, or Pichia pastoris, the animal cell is a mammalian cell, or hybridoma cell and the plant cell is a tobacco, a corn cell, a soybean cell, or a rice cell.

133\. (New) The method of claim 132, wherein the mammalian cell is a CHO cell, a COS cell, a HEK293T cell, a PER.C6 cell, a myeloma cell or a hybridoma cell.

134\. (New) A pharmaceutical composition comprising the expression vector of any one of claims 125-127 and a pharmaceutically acceptable carrier,
wherein the carrier is selected from the group consisting of a buffer, organic acid,
antioxidant, preservative, alkyl paraben, oligopeptide, protein, amino acid, hydrophilic polymer, carbohydrate, chelating agent, tonicifier, sugar, and surfactant.

135\. (New) The composition according to claim 134, wherein the buffer is acetate, Tris, phosphate, or citrate.

136\. (New) The composition according to claim 134, wherein the antioxidant is ascorbic acid or methionine.

137\. (New) The composition according to claim 134, wherein the preservative is octadecyldimethylbenzene, ammonium chloride, hexamethonium chloride, benzalkonium chloride, benzethonium chloride, phenol, butyl alcohol, or benzyl alcohol.

138\. (New) The composition according to claim 134, wherein the alkyl paraben is methyl paraben, propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, or m-cresol.

139\. (New) The composition according to claim 134, wherein the oligopeptide comprises at most ten residues.

140\. (New) The composition according to claim 134, wherein the protein is an immunoglobulin, gelatin, or serum albumin.

141\. (New) The composition according to claim 134, wherein the amino acid is glycine, glutamine, asparagine, histidine, arginine, or lysine.

142\. (New) The composition according to claim 134, wherein the hydrophilic polymer is polyvinylpyrrolidone.

143\. (New) The composition according to claim 134, wherein the carbohydrate is a monosaccharide, disaccharide, dextrin, glucose, or mannose.

144\. (New) The composition according to claim 134, wherein the chelating agent is EDTA.

145\. (New) The composition according to claim 134, wherein the tonicifier is trehalose or sodium chloride.

146\. (New) The composition according to claim 134, wherein the surfactant is polysorbate.

147\. (New) The composition according to claim 134, wherein said composition comprises a lyophilized formulation.

148\. (New) The composition according to claim 134, wherein said composition comprises an aqueous solution.

149\. (New) The composition according to claim 134, further comprising at least one therapeutic agent.

150\. (New) The composition according to claim 149, wherein the therapeutic agent is an antibody.

151\. (New) The composition according to claim 149, wherein the therapeutic agent is an anti-viral agent.

152\. (New) The composition according to claim 149, wherein the therapeutic agent is an anti-infective agent.

153\. (New) The composition according to claim 149, wherein the therapeutic agent is a cardioprotectant.

154\. (New) An antibody encoded and expressed by the expression vector of any one of claims 125-127, wherein the antigen is gp120.

155\. (New) A method of inhibiting HIV in a host comprising administering to the host the expression vector as claimed in any one of claims 125-127 under conditions whereby the vector expresses the antibody.

156\. (New) A method of inhibiting HIV in a host comprising administering to the host the composition of claim 134 under conditions whereby the vector expresses the antibody.

OFFICE ACTION:
Notice of Pre-AIA  or AIA  Status
The present application is being examined under the pre-AIA  first to invent provisions.
Priority
This application is a divisional of U.S. Application No. 18/150,957 filed January 6, 2023, now allowed, which is a continuation of U.S. Application No. 17/082,322 filed October 28, 2020, now U.S. Patent No. 11,584,789, which issued February 21, 2023, which is a continuation of U.S. Application No. 16/513,859 filed July 17, 2019 now U.S. Patent No. 10,865,234, which issued December 15, 2020, which is a continuation of U.S. Application Serial No. 16/275,936 filed February 14, 2019, now U.S. Patent No. 10,407,493, which issued on September 10, 2019, which is a continuation of U.S. Application Serial No. 15/918,343, filed March 12, 2018, now U.S. Patent No. 10,239,934 , which issued on March 26, 2019, which is a continuation of U.S. Application Serial No. 14/692,483 filed April 21, 2015, now U.S. Patent No. 9,920,111, which issued on March 20, 2018, which is a continuation of U.S. patent application Serial No. 12/726,245 filed March 17, 2010, now U.S. Patent 9,051,362, which issued on June 9, 2015, which claims the benefit of provisional applications USSN 61/161,010, filed March 17, 2009, USSN 61/165,829, filed April 1, 2009, USSN 61/224,739, filed July 10, 2009, and USSN 61/285,664, filed December 11, 2009 that is hereby acknowledged by the Examiner.
Information Disclosure Statement
The information disclosure statement (IDS) submitted on 06/05/2024 is in compliance with the provisions of 37 CFR 1.97.  Accordingly, the information disclosure statement(s) is/are being considered by the Examiner.
Examiner’s Statement of Reasons for Allowance
The Examiner’s statement of reasons for allowance is the following: the claims are directed to an expression vector that encodes and stably expresses in vivo an antibody comprising (a) a light chain variable region comprising complementarity determining regions (CDRs) having the amino acid sequences of SEQ ID NOS: 120, 121, and 44, and (b) a heavy chain variable region comprising CDRs having the amino acid sequences of SEQ ID NOS: 116, 117, and 118 that is free of the prior art of record.  The closest prior art, citing present inventor Chan- Hui et al. (US Patent 1131936) discloses a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture (see Abstract) and provides “monoclonal antibodies specifically directed against HIV. In certain embodiments, the invention provides human anti- HIV monoclonal antibodies including, but not limited to, 1443_C16 (PG16) (TCN-116), 1503 HO5 (PG16) (TCN-119), 1456 A12 (PG16) (TCN-117), 1469 M23 (PG16) (TCN-118), 1489_113 (PG16) (TCN-120), 1480_l08 (PG16), 1456 P20 (PG20), 1460_G14 (PGG14)’ (column 2 lines 46-67 and column 3 line 1); however, it does not teach an expression vector that encodes and stably expresses in vivo an antibody comprising (a) a light chain variable region comprising complementarity determining regions (CDRs) having the amino acid sequences of SEQ ID NOS: 120, 121, and 44, and (b) a heavy chain variable region comprising CDRs having the amino acid sequences of SEQ ID NOS: 116, 117, and 118.



CITED REFERENCE SUMMARIES: Ref US11584789: Claims:
1. A non-naturally occurring anti-HIV-1 PGC14 monoclonal antibody or antigen binding portion thereof comprising (a) a light chain variable region comprising complementarity determining regions having the amino acid sequences of SEQ ID NOS: 120, 121, and 44 and (b) a heavy chain variable region comprising complementarity determining regions having the amino acid sequences of SEQ ID NOS: 116, 117, and 118.
2. A non-naturally occurring anti-HIV-1 PGC14 monoclonal antibody or antigen binding portion thereof comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO: 38 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 37.
3. A non-naturally occurring anti-HIV-1 PGC14 monoclonal antibody or antigen binding portion thereof comprising (a) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO.: 24 and (b) a light chain sequence comprising the amino acid sequence of SEQ ID NO.: 26.
4. A pharmaceutical composition comprising the antibody of any one of claims 1 to 3 and a pharmaceutically acceptable carrier,
wherein the carrier is selected from the group consisting of a buffer, organic acid, antioxidant, preservative, alkyl paraben, oligopeptide, protein, amino acid, hydrophilic polymer, carbohydrate, chelating agent, tonicifier, sugar, and surfactant.
5. The composition according to claim 4, wherein the buffer is acetate, Tris, phosphate, or citrate.
6. The composition according to claim 4, wherein the antioxidant is ascorbic acid or methionine.
7. The composition according to claim 4, wherein the preservative is octadecyldimethylbenzene, ammonium chloride, hexamethonium chloride, benzalkonium chloride, benzethonium chloride, hexamethonium chloride, benzalkonium chloride, phenol, butyl alcohol, or benzyl alcohol.
8. The composition according to claim 4, wherein the alkyl paraben is methyl paraben, propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, or m-cresol.
9. The composition according to claim 4, wherein the oligopeptide comprises at most ten residues.
10. The composition according to claim 4, wherein the protein is an immunoglobulin, gelatin, or serum albumin.
11. The composition according to claim 4, wherein the amino acid is glycine, glutamine, asparagine, histidine, arginine, or lysine.
12. The composition according to claim 4, wherein the hydrophilic polymer is polyvinylpyrrolidone.
13. The composition according to claim 4, wherein the carbohydrate is a monosaccharide, disaccharide, dextrin, glucose, or mannose.
14. The composition according to claim 4, wherein the chelating agent is EDTA.
15. The composition according to claim 4, wherein the tonicifier is trehalose or sodium chloride.
16. The composition according to claim 4, wherein the sugar is sucrose, mannitol, trehalose, or sorbitol.
17. The composition according to claim 4, wherein the surfactant is polysorbate.
18. The composition according to claim 4, wherein said composition comprises a lyophilized formulation.
19. The composition according to claim 4, wherein said composition comprises an aqueous solution.
20. The composition according to claim 4, wherein the antibody is present at a concentration between 5-200 mg/mL.
21. The composition according to claim 4, wherein the antibody is present at a concentration between 10-100 mg/mL.
22. The composition according to claim 4, further comprising at least one therapeutic agent.
23. The composition of claim 22, wherein the therapeutic agent is a second antibody.
24. The composition of claim 22, wherein the therapeutic agent is an anti-viral agent.
25. The composition of claim 22, wherein the therapeutic agent is an anti-infective agent.
26. The composition of claim 22, wherein the therapeutic agent is a cardioprotectant.
27. The composition of claim 22, wherein the antibody is present at a concentration between 5-200 mg/mL.
28. The composition of claim 22, wherein the antibody is present at a concentration between 10-100 mg/mL.
29. The composition according to claim 4, wherein the antibody is encapsulated in microcapsules.
30. The composition of claim 22, wherein the antibody and the therapeutic agent are encapsulated in microcapsules.
31. The antibody of any one of claims 1-3, wherein the antigen is gp120.
Ref US10865234: Claims:
1. A pharmaceutical composition comprising
a non-naturally occurring anti-HIV-I PG9 monoclonal antibody or antigen binding portion thereof comprising:
(a) a light chain variable region comprising three complementarity determining regions comprising the amino acid sequences of SEQ ID NOS: 126, 127, and 45; and
(b) a heavy chain variable region comprising three complementarity determining regions comprising the amino acid sequences of SEQ ID NOS: 123, 124; and 7; and
a pharmaceutically acceptable carrier,
wherein the carrier is selected from the group consisting of a buffer, organic acid, antioxidant, preservative, alkyl paraben, oligopeptide, protein, amino acid, hydrophilic polymer, carbohydrate, chelating agent, tonicifier, sugar, and surfactant.
2. The composition of claim 1, wherein the antibody comprises:
(a) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 40; and
(b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 39.
3. The composition of claim 1, wherein the antibody comprises:
(a) a light chain sequence comprising the amino acid sequence of SEQ ID NO: 30; and
(b) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 28.
4. A pharmaceutical composition comprising
a non-naturally occurring anti-HIV-1 PG16 monoclonal antibody or antigen binding portion thereof comprising:
(a) a light chain variable region comprising three complementarity determining regions comprising the amino acid sequences of SEQ ID NOS: 92, 95, and 41, or SEQ ID NOS: 93, 95, and 41, or SEQ ID NOS: 97, 95, and 41; and
(b) a heavy chain variable region comprising three complementarity determining regions comprising the amino acid sequences of SEQ ID NOS: 88, 89, and 6, or SEQ ID NOS: 88, 98, and 6; and
a pharmaceutically acceptable carrier,
wherein the carrier is selected from the group consisting of a buffer, organic acid, antioxidant, preservative, alkyl paraben, oligopeptide, protein, amino acid, hydrophilic polymer, carbohydrate, chelating agent, tonicifier, sugar, and surfactant.
5. The composition of claim 4, wherein the antibody comprises:
(a) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 32 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 31; or
(b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 96 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 140; or
(c) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 51 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 48; or
(d) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 57 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 54; or
(e) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 32 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 60; or
(f) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 32 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 31.
6. The composition of claim 4, wherein the antibody comprises:
(a) a light chain sequence comprising the amino acid sequence of SEQ ID NO: 14 and a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 12; or
(b) a light chain sequence comprising the amino acid sequence of SEQ ID NO: 142 and a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 139; or
(c) a light chain sequence comprising the amino acid sequence of SEQ ID NO: 50 and a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 47; or
(d) a light chain sequence comprising the amino acid sequence of SEQ ID NO: 56 and a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 53; or
(e) a light chain sequence comprising the amino acid sequence of SEQ ID NO: 14 and a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 59; or
(f) a light chain sequence comprising the amino acid sequence of SEQ ID NO: 14 and a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 65.
7. The composition according to claim 1 or 4, wherein the buffer is acetate, Tris, phosphate, or citrate.
Ref US10407493: Claims:
1. An isolated and non-naturally occurring polynucleotide encoding (a) a light chain variable region comprising three complementarity determining regions comprising the amino acid sequences of SEQ ID NOS: 126, 127 and 45 and (b) a heavy chain variable region comprising three complementarity determining regions comprising the amino acid sequences of SEQ ID NOS: 123, 124 and 7.
2. An isolated and non-naturally occurring polynucleotide encoding (a) a light chain variable region comprising three complementarity determining regions comprising the amino acid sequences of SEQ ID NOS: 97, 95 and 41 and (b) a heavy chain variable region comprising three complementarity determining regions comprising the amino acid sequences of SEQ ID NOS: 88, 89 and 6.
3. An isolated and non-naturally occurring polynucleotide encoding (a) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 30 and (b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 28.
4. An isolated and non-naturally occurring polynucleotide comprising (a) a light chain variable region comprising the nucleotide sequence of SEQ ID NO: 125 and (b) a heavy chain variable region comprising the nucleotide sequence of SEQ ID NO: 122.
5. An isolated and non-naturally occurring polynucleotide encoding (a) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 14 and (b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 12.
6. An isolated and non-naturally occurring polynucleotide comprising (a) a light chain variable region comprising the nucleotide sequence of SEQ ID NO: 100 and (b) a heavy chain variable region comprising the nucleotide sequence of SEQ ID NO: 99.
7. The polynucleotide of any one of claims 1-6, wherein the polynucleotide is a single-stranded DNA, a double-stranded DNA or an RNA molecule.
8. The polynucleotide of claim 7, wherein the single-stranded DNA is a coding or antisense DNA, the double-stranded DNA is a genomic, cDNA or synthetic DNA and the RNA molecule is an hnRNA or a mRNA.
9. One or more vectors encoding the nucleic acid sequence of any one of claims 1-6.
10. The one or more vectors of claim 9, wherein one vector encodes the light chain sequence and another vector encodes the heavy chain sequence.
11. The one or more vectors of claim 9, wherein one vector encodes the light chain sequence and a heavy chain sequence.
12. The one or more vectors of claim 9, wherein the vector is viral vector, a plasmid vector, a plant expression vector or a yeast expression vector.
13. The one or more vectors of claim 12, wherein the viral vector is an adeno-associated virus vector.
14. A cell containing and expressing the one or more vectors of claim 9.
15. The cell of claim 14, wherein the cell is a prokaryotic host cell or a eukaryotic host cell.
16. The cell of claim 15, wherein the prokaryotic host cell is Escherichia coli, the eucaryotic host cell is a yeast cell, an animal cell or a plant cell.
17. The eucaryotic host cell of claim 16, wherein the yeast cell is Saccharomyces cerevisiae, Schizosaccharomyces pombe, or Pichia pastoris, the animal cell is a mammalian cell, or hybridoma cell and the plant cell is a tobacco, a corn cell, a soybean cell, or a rice cell.
18. The eucaryotic host cell of claim 17, wherein the mammalian cell is a CHO cell, a COS cell, a HEK293T cell, a PER.C6 cell, a myeloma cell or a hybridoma cell.
19. A pharmaceutical composition comprising the polynucleotide of any one of claims 1-6 and a pharmaceutically acceptable excipient.
20. A method of inhibiting HIV in a host comprising administering to the host a pharmaceutical composition of claim 19 under conditions whereby the polynucleotide or the vector expresses the antibody.
Ref US10239934: Claims:
1. A method of inhibiting HIV in a host comprising administering to the host a non-naturally occurring monoclonal anti-HIV antibody, designated 1496 C09 (PG9) or antigen binding portion thereof comprising (a) a light chain variable region comprising complementarity determining regions (CDRs) having the amino acid sequences of SEQ ID NOS: 45, 126 and 127 and (b) a heavy chain variable region comprising CDRs having the amino acid sequences of SEQ ID NOS: 7, 123 and 124.
2. A method of inhibiting HIV in a host comprising administering to the host a non-naturally occurring monoclonal anti-HIV antibody, designated 1443 C16 (PG16) or antigen binding portion thereof comprising (a) a light chain variable region comprising CDRs having the amino acid sequences of SEQ ID NOS: 41, 95, and 97 and (b) a heavy chain variable region comprising CDRs having the amino acid sequences of SEQ ID NOS: 6, 88 and 89.
3. A method of inhibiting HIV in a host comprising administering to the host a non-naturally occurring monoclonal anti-HIV PG9 antibody or antigen binding portion thereof comprising a light chain sequence of SEQ ID NO: 30 and a heavy chain sequence of SEQ ID NO: 28.
4. A method of inhibiting HIV in a host comprising administering to the host a non-naturally occurring monoclonal anti-HIV PG16 antibody or antigen binding portion thereof comprising a light chain sequence of SEQ ID NO: 14 and a heavy chain sequence of SEQ ID NO: 12.
5. The method of any one of claims 1-4, wherein the antibody or antigen binding portion thereof is administered with a pharmaceutically acceptable carrier.
6. An expression vector that encodes and stably expresses in vivo an antibody comprising each of a light chain sequence of SEQ ID NO: 30 and a heavy chain sequence of SEQ ID NO: 28.
7. An expression vector that encodes and stably expresses in vivo an antibody comprising each of a light chain sequence of SEQ ID NO: 14 and a heavy chain sequence of SEQ ID NO: 12.
8. An expression vector that encodes and stably expresses in vivo an antibody comprising (a) a light chain variable region comprising complementarity determining regions (CDRs) having the amino acid sequences of SEQ ID NOS: 45, 126 and 127 and (b) a heavy chain variable region comprising CDRs having the amino acid sequences of SEQ ID NOS: 7, 123 and 124.
9. An expression vector that encodes and stably expresses in vivo an antibody comprising (a) a light chain variable region comprising CDRs having the amino acid sequences of SEQ ID NOS: 41, 95, and 97 and (b) a heavy chain variable region comprising CDRs having the amino acid sequences of SEQ ID NOS: 6, 88 and 89.
10. The expression vector of any one of claims 6-9 wherein the expression vector comprises a viral based vector.
11. A pharmaceutical composition comprising the expression vector of any one of claims 6-9.
12. A pharmaceutical composition comprising the expression vector of any one of claims 6-9 and a pharmaceutically acceptable carrier.
13. A method of inhibiting HIV in a host comprising administering to the host the expression vector as claimed in any one of claims 6-9 under conditions whereby the vector expresses the antibody.
14. A method of inhibiting HIV in a host comprising administering to the host the composition as claimed in claim 12 under conditions whereby the vector expresses the antibody.
Ref US9920111: Claims:
1. A non-naturally occurring anti-HIV-1 PG9 monoclonal antibody or antigen binding portion thereof comprising (a) a light chain variable region comprising complementarity determining regions having the amino acid sequences of SEQ ID NOS: 45, 126 and 127 and (b) a heavy chain variable region comprising complementarity determining regions having the amino acid sequences of SEQ ID NOS: 7, 123 and 124.
2. A non-naturally occurring anti-HIV-1 PG16 monoclonal antibody or antigen binding portion thereof comprising (a) a light chain variable region comprising complementarity determining regions having the amino acid sequences of SEQ ID NOS: 41, 95 and 97 and (b) a heavy chain variable region comprising complementarity determining regions having the amino acid sequences of SEQ ID NOS: 6, 88 and 89.
3. A non-naturally occurring anti-HIV-1 PG9 monoclonal antibody or antigen binding portion thereof comprising (a) a light chain variable region comprising amino acid sequence SEQ ID NO: 40 and (b) a heavy chain variable region comprising amino acid sequence of SEQ ID NO: 39.
4. A non-naturally occurring anti-HIV-1 PG16 monoclonal antibody or antigen binding portion thereof comprising (a) a light chain variable region comprising amino acid sequence SEQ ID NO: 32 and (b) a heavy chain variable region comprising amino acid sequence of SEQ ID NO: 31.
5. A non-naturally occurring anti-HIV-1 PG9 monoclonal antibody or antigen binding portion thereof comprising a heavy chain sequence of SEQ ID NO.: 28 and a light chain sequence of SEQ ID NO.: 30.
6. A non-naturally occurring anti-HIV-1 PG16 monoclonal antibody or antigen binding portion thereof comprising a heavy chain sequence of SEQ ID NO.: 12 and a light chain sequence of SEQ ID NO.: 14.
7. A pharmaceutical composition comprising the antibody of any one of claims 1 to 6 and a pharmaceutically acceptable carrier.
8. The antibody of any one of claims 1-6, wherein the antigen is gp120.
Ref US9051362: Claims:
1. A method of inhibiting HIV in a host comprising administering to the host an isolated fully human anti-HIV-1 monoclonal antibody, designated 1496 C09 (PG9), comprising a heavy chain sequence of SEQ ID NO.: 39 and a light chain sequence of SEQ ID NO.: 40.
2. A method of inhibiting HIV in a host comprising administering to the host an isolated fully human anti-HIV-1 monoclonal antibody, designated 1443 C16 (PG16), comprising a heavy chain sequence of SEQ ID NO.: 31 and a light chain sequence of SEQ ID NO.: 32.
3. A method of inhibiting HIV in a host comprising administering to the host a composition comprising an isolated fully human anti-HIV-1 monoclonal antibody, designated 1496 C09 (PG9), comprising a heavy chain sequence of SEQ ID NO.: 39 and a light chain sequence of SEQ ID NO.: 40.
4. A method of inhibiting HIV in a host comprising administering to the host a composition comprising an isolated fully human anti-HIV-1 monoclonal antibody, designated 1443 C16 (PG16) comprising a heavy chain sequence of SEQ ID NO.: 31 and a light chain sequence of SEQ ID NO.: 32.
5. A method of inhibiting HIV in a host comprising administering to the host a pharmaceutical composition comprising an isolated fully human anti-HIV-1 monoclonal antibody, designated 1496 C09 (PG9), comprising a heavy chain sequence of SEQ ID NO.: 39 and a light chain sequence of SEQ ID NO.: 40 and a pharmaceutically acceptable carrier.
6. A method of inhibiting HIV in a host comprising administering to the host a pharmaceutical composition comprising an isolated fully human anti-HIV-1 monoclonal antibody, designated 1443 C16 (PG16), comprising a heavy chain sequence of SEQ ID NO.: 31 and a light chain sequence of SEQ ID NO.: 32 and a pharmaceutically acceptable carrier.
7. An expression vector that encodes and stably expresses in vivo an antibody comprising each of a heavy chain sequence of SEQ ID NO:39 and a light chain sequence of SEQ ID NO:40, or each of a heavy chain sequence of SEQ ID NO:31 and a light chain sequence of SEQ ID NO: 32.
8. The expression vector of claim 7 wherein the vector contains and expresses in vivo an antibody comprising a heavy chain sequence of S
[Truncated to input limit]